"We know the devil will be in the detail and there is a huge amount of work ahead in negotiating and defining how we implement the reforms that are so urgently needed," said Medicines Australia chief executive and HTA review reference committee member Liz de Somer. …
Medicines Australia says the 'devil is in the detail' of HTA review options paper
January 29, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Stakeholder backing for another PBS co-pay reduction
March 20, 2025 - - Latest News -
If our own government isn't going to do anything, then we can only hope for intervention
March 20, 2025 - - Latest News -
US price negotiation power reveals a very different approach to patient input
March 20, 2025 - - Latest News -
Brisbane-based drugmaker QBiotics celebrates 25 years since its creation
March 19, 2025 - - Australian Biotech -
Imugene's azer-cel granted FDA Fast Track Designation in blood cancer
March 19, 2025 - - Australian Biotech -
Island raises $2.72 million through exercise of listed options
March 19, 2025 - - Australian Biotech -
All manufacturers decide to participate in the second cycle of US price negotiation
March 19, 2025 - - Latest News